Should I buy or sell Adagene stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADAG shares. View ADAG analyst ratings or view top-rated stocks .

What is Adagene's stock price target for 2024?

1 equities research analysts have issued twelve-month price objectives for Adagene's stock. Their ADAG share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 89.4% from the stock's current price. View analysts price targets for ADAG or view top-rated stocks among Wall Street analysts .

How have ADAG shares performed in 2024?

Adagene's stock was trading at $1.9314 at the start of the year. Since then, ADAG shares have increased by 36.7% and is now trading at $2.64. View the best growth stocks for 2024 here .

Are investors shorting Adagene?

Adagene saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 13,700 shares, a decrease of 38.6% from the March 15th total of 22,300 shares. Based on an average daily trading volume, of 105,400 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are short sold. View Adagene's Short Interest .

When did Adagene IPO?

Adagene (ADAG) raised $133 million in an initial public offering on Tuesday, February 9th 2021. The company issued 7,400,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies acted as the underwriters for the IPO and China Renaissance was co-manager.

How do I buy shares of Adagene?

Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:ADAG

Adagene (ADAG) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ADAG Stock Alerts

$2.64

0.00 (0.00%)

(As of 05:21 PM ET)

Compare

Today's Range: $2.51
▼
$2.64
50-Day Range: $2.50
▼
$3.68
52-Week Range: $1.10
▼
$4.38

Volume: 5,364 shs
Average Volume: 93,059 shs
Market Capitalization: $116.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Get Adagene alerts:

Adagene MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 89.4% Upside
$5.00 Price Target
Short Interest: Healthy
0.04% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.90) to ($1.42) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.65 out of 5 stars

Medical Sector

459th out of 918 stocks

Pharmaceutical Preparations Industry

207th out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
Adagene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Adagene has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.04% of the float of Adagene has been sold short.
Short Interest Ratio / Days to Cover
Adagene has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Adagene has recently decreased by 38.57%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Adagene does not currently pay a dividend.
Dividend Growth
Adagene does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADAG.

2.7

News and Social Media Coverage

News Sentiment
Adagene has a news sentiment score of 1.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adagene insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 9.51% of the stock of Adagene is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Adagene are expected to decrease in the coming year, from ($0.90) to ($1.42) per share.
Price to Book Value per Share Ratio
Adagene has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Adagene Stock (NASDAQ:ADAG)

Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

ADAG Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ADAG Stock News Headlines

April 11, 2024 | americanbankingnews.com

Adagene Inc. (NASDAQ:ADAG) Short Interest Down 38.6% in March

April 10, 2024 | investing.com

Morgan Stanley lifts Adagene stock target on positive data

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

March 31, 2024 | finanznachrichten.de

Adagene Inc.: Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

March 29, 2024 | globenewswire.com

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

March 7, 2024 | globenewswire.com

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

February 27, 2024 | globenewswire.com

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

February 9, 2024 | finance.yahoo.com

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

January 21, 2024 | seekingalpha.com

Week In Review: Lee's Pharm Signs $138M Agreement For China Rights To Heart Failure Therapy

January 19, 2024 | msn.com

Mesoblast rises after cell therapy gets FDA rare pediatric disease designation

January 18, 2024 | benzinga.com

How Is The Market Feeling About Adagene?

January 17, 2024 | realmoney.thestreet.com

Morgan Stanley 'encouraged' by 2 cPRs reported by Adagene

January 17, 2024 | benzinga.com

Why Is Cancer Focused Adagene Stock Plummeting Today?

January 17, 2024 | msn.com

Adagene falls after trial data for cancer therapy

January 16, 2024 | finance.yahoo.com

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

January 10, 2024 | finance.yahoo.com

Adagene Inc.'s (NASDAQ:ADAG) market cap surged US$34m last week, retail investors who have a lot riding on the company were rewarded

January 4, 2024 | finance.yahoo.com

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

December 28, 2023 | msn.com

NKGen doses first patient in Phase 1/2a Alzheimer's study

December 20, 2023 | realmoney.thestreet.com

Adagene price target lowered by 40c at Morgan Stanley, here's why

December 19, 2023 | markets.businessinsider.com

Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors

November 3, 2023 | finance.yahoo.com

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

October 13, 2023 | finance.yahoo.com

Are Medical Stocks Lagging Medpace (MEDP) This Year?

October 12, 2023 | finance.yahoo.com

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

October 5, 2023 | msn.com

Adagene Inc - ADR (ADAG) Price Target Increased by 9.87% to 14.04

October 4, 2023 | markets.businessinsider.com

Adagene’s Strong Potential: A Buy Rating Backed by Evorpacept Trials and Promising CD47-Targeted Therapies

September 9, 2023 | finance.yahoo.com

Potential Upside For Adagene Inc. (NASDAQ:ADAG) Not Without Risk

See More Headlines

Receive ADAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ADAG
CUSIP: N/A
CIK: 1818838
Web: www.adagene.com
Phone: 86-512-8777-3632
Fax: N/A
Employees: 174
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +89.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.19
Current Ratio: 3.61
Quick Ratio: 3.61

Sales & Book Value

Annual Sales: $18.11 million
Price / Sales: 6.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.61 per share
Price / Book: 1.64

Miscellaneous

Outstanding Shares: 44,120,000
Free Float: 34,764,000
Market Cap: $116.48 million
Optionable: Not Optionable
Beta: 0.44

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Peter P. Luo Ph.D. (Age 58)
Co- Founder, Chairman, CEO and President of R&D
Mr. Man Kin Tam M.B.A. (Age 47)
CFO & Director
Dr. Jc Xu M.D. (Age 59)
Ph.D., Chief Scientific Officer
Ms. Ami Celeste Knoefler
Vice President of Investor Relations & Corporate Communications
Ms. Ling Zhou
Head of Human Resources
Dr. Qinghai Zhao (Age 63)
Chief Manufacturing Officer
Ms. Yan Li M.B.A. (Age 49)
Senior VP of Bioinformatics & Information Technology and Director
Ms. Xiaohong She (Age 57)
Senior VP & Head of Clinical Operations
Dr. Guizhong Liu Ph.D. (Age 53)
Senior Vice President of Early Drug Discovery
Mr. Alexander Goergen (Age 37)
VP & Head of Business Development

Key Competitors

View All Competitors

Institutional Ownership

WuXi AppTec Co. Ltd.
Bought 4,225,696 shares on 2/6/2024
Ownership: 9.641%

View All Institutional Transactions

ADAG Stock Analysis - Frequently Asked Questions

Should I buy or sell Adagene stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADAG shares.
View ADAG analyst ratings or view top-rated stocks.
What is Adagene's stock price target for 2024?: 1 equities research analysts have issued twelve-month price objectives for Adagene's stock. Their ADAG share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 89.4% from the stock's current price.
View analysts price targets for ADAG or view top-rated stocks among Wall Street analysts.
How have ADAG shares performed in 2024?: Adagene's stock was trading at $1.9314 at the start of the year. Since then, ADAG shares have increased by 36.7% and is now trading at $2.64.
View the best growth stocks for 2024 here.
Are investors shorting Adagene?: Adagene saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 13,700 shares, a decrease of 38.6% from the March 15th total of 22,300 shares. Based on an average daily trading volume, of 105,400 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are short sold.
View Adagene's Short Interest.

When did Adagene IPO?: Adagene (ADAG) raised $133 million in an initial public offering on Tuesday, February 9th 2021. The company issued 7,400,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies acted as the underwriters for the IPO and China Renaissance was co-manager.
How do I buy shares of Adagene?: Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADAG) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial